Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...